Uniqure NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
QURE Nasdaq 8731 http://www.uniqure.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Uniqure NV

uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference - Feb 27th, 2020 12:00 pm
Why Earnings Season Could Be Great for uniQure (QURE) - Feb 26th, 2020 1:41 pm
Before You Buy uniQure N.V. (NASDAQ:QURE), Consider Its Volatility - Feb 21st, 2020 3:48 pm
UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Feb 20th, 2020 5:31 pm
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) - Feb 4th, 2020 12:00 pm
uniQure to Participate in Multiple Upcoming Industry Conferences in February - Jan 31st, 2020 12:00 pm
Cambridge startup raises $110M for re-doseable gene therapies - Jan 10th, 2020 7:20 pm
uniQure (NASDAQ:QURE) Shareholders Have Enjoyed A Magnificent 1077% Share Price Gain - Jan 7th, 2020 5:12 pm
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A - Dec 24th, 2019 2:30 pm
One particular field of drug development could dominate M&A in 2020 - Dec 19th, 2019 3:27 pm
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach - Dec 19th, 2019 12:00 pm
5 Biotech Stocks That Have More Than Doubled This Year - Dec 17th, 2019 2:11 pm
Will uniQure Continue to Surge Higher? - Dec 17th, 2019 12:02 pm
Atlas, MPM, Partners funnel $49M into a new gene-silencing startup - Dec 17th, 2019 11:00 am
5 Biotech Stocks Set for Continued Rally in 2020 - Dec 16th, 2019 2:34 pm
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B - Dec 8th, 2019 9:00 pm
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics - Dec 6th, 2019 2:33 pm
Astellas-Audentes Deal Likely to Ignite More Acquisitions - Dec 5th, 2019 9:32 pm
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal - Dec 5th, 2019 3:12 pm
Gene Therapy the Next Best Thing: Here's Why (Revised) - Dec 5th, 2019 8:49 am